Does Sensitive Cyp3a Substrates Interact with Finerenone?
Sensitive Cyp3a Substrates and Finerenone have a moderate drug interaction according to U.S. FDA drug labeling data. Finerenone 40 mg is a weak CYP2C8 inhibitor and increases exposure of CYP2C8 substrates; monitor patients more frequently for adverse reactions. The mechanism involves finerenone weakly inhibits cyp2c8 at 40 mg dose. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Finerenone Class
- Nonsteroidal Mineralocorticoid-Receptor Antagonist
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Sensitive Cyp3a Substrates and Finerenone occurs because finerenone weakly inhibits cyp2c8 at 40 mg dose. Clinically, this means finerenone 40 mg is a weak cyp2c8 inhibitor and increases exposure of cyp2c8 substrates; monitor patients more frequently for adverse reactions. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Sensitive Cyp3a Substrates and your doctor is considering prescribing Finerenone (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider